Product: | Sunitinib-d10 | ||||
---|---|---|---|---|---|
Catalog Number: | D13623 | ||||
Synonyms: |
N-[2-(Diethyl-d10)aminoethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; Sutent-d10; SU-11248-d10 |
||||
Pricing: |
|
||||
Formula: | C22H17D10FN4O7 | ||||
Enrichment: | 98%D | ||||
Molecular Weight: | 408.54 | ||||
Structure: | |||||
Category: | Anti-cancer compounds | ||||
Literature References: |
Demetri GD et al., Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet, 2006, 368 (9544): 1329–1338.; Motzer RJ et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med, 2007, 356 (2): 115–124. |
||||
MSDS: | |||||
Applications: | A labeled multi-targeted receptor tyrosine kinase inhibitor. Used to treat renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. |